Anti-glomerular Basement Membrane Disease: What Have We Learned?
Journal
Advances in anatomic pathology
ISSN: 1533-4031
Titre abrégé: Adv Anat Pathol
Pays: United States
ID NLM: 9435676
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
pubmed:
30
9
2020
medline:
7
4
2021
entrez:
29
9
2020
Statut:
ppublish
Résumé
Since the first clinicopathologic description by Ernest Goodpasture of a patient whom he considered to have died of influenza in 1919, substantial progress has been made in our knowledge of anti-glomerular basement membrane disease. This has led to a significant decrease in the morbidity and mortality associated with this disease. In this paper, we aim to review the literature that has enhanced our understanding of classic anti-glomerular basement membrane disease and its clinic-pathologic variants in the key areas of immunopathogenesis and histopathology. We also summarize varied clinical presentations and therapeutic strategies.
Identifiants
pubmed: 32991349
doi: 10.1097/PAP.0000000000000280
pii: 00125480-202101000-00006
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
59-65Références
McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12:1162–1172.
Gulati K, McAdoo SP. Anti-glomerular basement membrane disease. Rheum Dis Clin North Am. 2018;44:651–673.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11.
Goodpasture E. The significance of certain pulmonary lesions in relation to the etiology of influenza. Am J Med Sci. 1919;158:863–870.
Parkin TW, Rusted IE, Burchell HB, et al. Hemorrhagic and interstitial pneumonitis with nephritis. Am J Med. 1955;18:220–236.
Stanton MC, Tange JD. Goodpasture’s syndrome (pulmonary haemorrhage associated with glomerulonephritis). Australas Ann Med. 1958;7:132–144.
West SC, Arulkumaran N, Ind PW, et al. Pulmonary-renal syndrome: a life threatening but treatable condition. Postgrad Med J. 2013;89:274–283.
Scheer RL, Grossman MA. Immune aspects of the glomerulonephritis associated with pulmonary hemorrhage. Ann Intern Med. 1964;60:1009–1021.
Duncan DA, Drummond KN, Michael AF, et al. Pulmonary hemorrhage and glomerulonephritis. Report OS six cases and study of the renal lesion by the fluorescent antibody technique and electron microscopy. Ann Intern Med. 1965;62:920–938.
Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med. 1967;126:989–1004.
Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int. 1973;3:74–89.
Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63:1164–1177.
Tang W, McDonald SP, Hawley CM, et al. Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney Int. 2013;83:503–510.
Shah MK, Hugghins SY. Characteristics and outcomes of patients with Goodpasture’s syndrome. South Med J. 2002;95:1411–1418.
Savage CO, Pusey CD, Bowman C, et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed). 1986;292:301–304.
Canney M, O’Hara PV, McEvoy CM, et al. Spatial and temporal clustering of anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2016;11:1392–1399.
Lingaraj U, Mallappa SS, Neminah RE, et al. A “Mini-Epidemic” of anti-glomerular basement membrane disease: clinical and epidemiological study. Saudi J Kidney Dis Transpl. 2017;28:1057–1063.
Johnson JP, Whitman W, Briggs WA, et al. Plasmapheresis and immunosuppressive agents in antibasement membrane antibody-induced Goodpasture’s syndrome. Am J Med. 1978;64:354–359.
Levy JB, Turner AN, Rees AJ, et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134:1033–1042.
Qunibi WY, Taylor K, Knight TF, et al. Nephrotic syndrome in anti-GBM antibody mediated glomerulonephritis. South Med J. 1979;72:1396–1398.
Jia XY, Hu SY, Chen JL, et al. The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy. Kidney Int. 2014;85:945–952.
Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet. 1983;2:1390–1393.
Kitagawa W, Imai H, Komatsuda A, et al. The HLA-DRB1*1501 allele is prevalent among Japanese patients with anti-glomerular basement membrane antibody-mediated disease. Nephrol Dial Transplant. 2008;23:3126–3129.
Fogo AB, Lusco MA, Najafian B, et al. AJKD atlas of renal pathology: anti-glomerular basement membrane antibody-mediated glomerulonephritis. Am J Kidney Dis. 2016;68:e29–e30.
Lombard CM, Colby TV, Elliott CG. Surgical pathology of the lung in anti-basement membrane antibody-associated Goodpasture’s syndrome. Hum Pathol. 1989;20:445–451.
Jayne DR, Marshall PD, Jones SJ, et al. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 1990;37:965–970.
Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66:1535–1540.
Rutgers A, Slot M, van Paassen P, et al. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis. 2005;46:253–262.
Canney M, Little MA. ANCA in anti-GBM disease: moving beyond a one-dimensional clinical phenotype. Kidney Int. 2017;92:544–546.
McAdoo S, Tanna A, Hruskova Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92:693–702.
Troxell ML, Houghton DC. Atypical anti-glomerular basement membrane disease. Clin Kidney J. 2016;9:211–221.
Liang D, Liang S, Xu F, et al. Clinicopathological features and outcome of antibody-negative anti-glomerular basement membrane disease. J Clin Pathol. 2019;72:31–37.
Nasr SH, Collins AB, Alexander MP, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int. 2016;89:897–908.
Sporinova B, McRae SA, Muruve DA, et al. A case of aggressive atypical anti-GBM disease complicated by CMV pneumonitis. BMC Nephrol. 2019;20:29.
Patel D, Nivera N, Tunkel AR. Anti-glomerular basement membrane disease superimposed on membranous nephropathy: a case report and review of the literature. J Med Case Rep. 2010;4:237.
Basford AW, Lewis J, Dwyer JP, et al. Membranous nephropathy with crescents. J Am Soc Nephrol. 2011;22:1804–1808.
Savige JA, Dowling J, Kincaid-Smith P. Superimposed glomerular immune complexes in anti-glomerular basement membrane disease. Am J Kidney Dis. 1989;14:145–153.
Kotanko P, Pusey CD, Levy JB. Recurrent glomerulonephritis following renal transplantation. Transplantation. 1997;63:1045–1052.
Sauter M, Schmid H, Anders HJ, et al. Loss of a renal graft due to recurrence of anti-GBM disease despite rituximab therapy. Clin Transplant. 2009;23:132–136.
Khandelwal M, McCormick BB, Lajoie G, et al. Recurrence of anti-GBM disease 8 years after renal transplantation. Nephrol Dial Transplant. 2004;19:491–494.
Pedchenko V, Bondar O, Fogo AB, et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med. 2010;363:343–354.
Byrne MC, Budisavljevic MN, Fan Z, et al. Renal transplant in patients with Alport’s syndrome. Am J Kidney Dis. 2002;39:769–775.
Kruegel J, Rubel D, Gross O. Alport syndrome—insights from basic and clinical research. Nat Rev Nephrol. 2013;9:170–178.
Kashtan CE. Renal transplantation in patients with Alport syndrome. Pediatr Transplant. 2006;10:651–657.
Browne G, Brown PA, Tomson CR, et al. Retransplantation in Alport post-transplant anti-GBM disease. Kidney Int. 2004;65:675–681.
Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int. 2012;2:139–274.
Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149–162.
Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004;15:717–721.
Alchi B, Griffiths M, Sivalingam M, et al. Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transplant. 2015;30:814–821.
van Daalen EE, Jennette JC, McAdoo SP, et al. Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol. 2018;13:63–72.
Touzot M, Poisson J, Faguer S, et al. Rituximab in anti-GBM disease: a retrospective study of 8 patients. J Autoimmun. 2015;60:74–79.
Bandak G, Jones BA, Li J, et al. Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy. Clin Kidney J. 2014;7:53–56.